Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
About the study
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- History of gout
- Occurrence of ≥ 2 self-reported gout flares in the last 12 months
- Body weight no less than 50 kg
- Patients who are NOT on approved urate-lowering therapy (ULT) must have sUA ≥ 7 mg/dL
- Patients who are on medically appropriate ULT must have sUA > 6 mg/dL
- Serum creatinine must be < 3.0 mg/dL and estimated CLcr ≥ 30 mL/min
EXCLUSION CRITERIA
Exclusion Criteria:
- Malignancy within 5 years, except for successfully treated basal or squamous cell carcinoma of the skin
- Pregnant or breastfeeding
- History of symptomatic kidney stones within the past 6 months
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Gout,Arthritis, Gouty,Hyperuricemia,Gout Chronic
Age
18 - 85
Phase
PHASE3
Participants needed
750
Est. Completion Date
Apr 30, 2026
Treatment type
INTERVENTIONAL
Sponsor
Arthrosi Therapeutics
ClinicalTrials.gov identifier
NCT06846515
Study number
AR882-301
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?